title: Nanoparticles in melanoma.
abstract: Malignant melanoma is one of the most common causes of cancer and cancer deaths in young people. Until few years ago, scarce drugs have proven efficacy in metastatic setting. However, in the recent years, the treatment of metastatic malignant melanoma has undergone the incorporation of effective treatment such as immunotherapy, the use of tyrosine kinase inhibitors and the emergence of other cytostatic compounds, like the nanoparticles. This review aims to propose a standardization to classify the different types of nanoparticles, according to chemical aspects, and update the clinical research with nanoparticles and their use in melanoma field.
authors.forename: M A
authors.initials: MA
authors.lastname: Berciano-Guerrero
authors.forename: A
authors.initials: A
authors.lastname: Montesa-Pino
authors.forename: G
authors.initials: G
authors.lastname: Castaneda-Penalvo
authors.forename: L
authors.initials: L
authors.lastname: Munoz-Fernandez
authors.affiliation: Medical Oncology Section, Hospital Regional Universitario Carlos Haya, Malaga, Avda. Carlos Haya s/n; 29010 Malaga, Spain. migueberci@gmail.com.
authors.forename: J
authors.initials: J
authors.lastname: Rodriguez-Flores
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D008545:Melanoma / Q000628:therapy*; D053758:Nanoparticles; D012878:Skin Neoplasms / Q000628:therapy*